Previous close | 16.22 |
Open | 16.39 |
Bid | 6.60 x 900 |
Ask | 19.88 x 2200 |
Day's range | 15.91 - 17.17 |
52-week range | 14.65 - 33.09 |
Volume | |
Avg. volume | 219,109 |
Market cap | 716.883M |
Beta (5Y monthly) | 1.01 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will present at the H.C. Wainwright Global Investment Conference. The webcast of the presentation will be available on-demand starting on May 24, 2022 at 7:00 a.m. ET and will be con
- Zenocutuzumab clinical abstract selected for oral presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting- Company to host investor call on Sunday, June 5 at 6:00 p.m. CT- Clinical data update of petosemtamab (Peto) and MCLA-129 planned for second half of 2022 UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 09, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we”, or “our”), a clinical-stage oncology company developing innovative, ful
UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 27, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the selection of an abstract for oral presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, being held in Chicago, Illinois on June 3-7, 2022. The presentation will highlight upd